Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines

被引：43

作者：

Hegerle, Nicolas ^{[1
]}

Guiso, Nicole

机构：

[1] Inst Pasteur, Unite Prevent & Therapies Mol Malad Humaines, F-75015 Paris, France

来源：

EXPERT REVIEW OF VACCINES | 2014年 / 13卷 / 09期

关键词：

acellular vaccine; autotransporter; bacterial evolution; Bordetella pertussis; pertactin; vaccine selection; ADENYLATE-CYCLASE TOXIN; VIRULENCE FACTORS; WHOLE-CELL; FILAMENTOUS HEMAGGLUTININ; BOOSTER VACCINATION; NEGATIVE VARIANTS; GENOMIC CONTENT; WHOOPING-COUGH; PARAPERTUSSIS; IMMUNITY;

D O I：

10.1586/14760584.2014.932254

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Bordetella pertussis causes whooping cough in humans, a highly transmissible respiratory disease life threatening for unvaccinated infants. Vaccination strategies were thus introduced worldwide with great success in developed countries reaching high vaccine coverage with efficacious vaccines. In the late 20th/early 21st century, acellular pertussis vaccines replaced whole cell pertussis vaccines but B. pertussis still circulates and evolves in humans, its only known reservoir. The latest transformation of this pathogen, and of its close relative Bordetella parapertussis, is the loss of pertactin production, a virulence factor included in different acellular pertussis vaccines. The real impact of this evolution on acellular pertussis vaccines efficacy and effectiveness should be assessed through standardized surveillance and isolation of B. pertussis and B. parapertussis worldwide.

引用

页码：1135 / 1146

页数：12

共 94 条

[11]

Bordet J, 1906, Les. Annales lInstitut Pasteur, V20, P731

[12] Bordetella parapertussis isolates not expressing pertactin circulating in France [J].

Bouchez, V. ;

Brun, D. ;

Dore, G. ;

Njamkepo, E. ;

Guiso, N. .

CLINICAL MICROBIOLOGY AND INFECTION, 2011, 17 (05) :675-682

[13] First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin [J].

Bouchez, V. ;

Brun, D. ;

Cantinelli, T. ;

Dore, G. ;

Njamkepo, E. ;

Guiso, N. .

VACCINE, 2009, 27 (43) :6034-6041

[14] Genomic Content of Bordetella pertussis Clinical Isolates Circulating in Areas of Intensive Children Vaccination [J].

Bouchez, Valerie ;

Caro, Valerie ;

Levillain, Erwan ;

Guigon, Ghislaine ;

Guiso, Nicole .

PLOS ONE, 2008, 3 (06)

[15] Polymorphism of repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica [J].

Boursaux-Eude, C ;

Guiso, N .

INFECTION AND IMMUNITY, 2000, 68 (08) :4815-4817

[16] Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools [J].

Carbonetti, Nicholas H. .

FUTURE MICROBIOLOGY, 2010, 5 (03) :455-469

[17]

Carlsson Rose-Marie, 2009, Vaccine, V27, P5709, DOI 10.1016/j.vaccine.2009.07.092

[18] Is the sequenced Bordetella pertussis strain Tohama I representative of the species? [J].

Caro, Valerie ;

Bouchez, Valerie ;

Guiso, Nicole .

JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (06) :2125-2128

[19] Bordetella pertussis, Finland and France [J].

Caro, Valerie ;

Elomaa, Annika ;

Brun, Delphine ;

Mertsola, Jussi ;

He, Qiushui ;

Guiso, Nicole .

EMERGING INFECTIOUS DISEASES, 2006, 12 (06) :987-989

[20] Structure of bacterial lipopolysaccharides [J].

Caroff, M ;

Karibian, D .

CARBOHYDRATE RESEARCH, 2003, 338 (23) :2431-2447

← 1 2 3 4 5 6 7 8 9 10 →